

TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY CYTOKINE
INHIBITORS INTO ORTHOPEDIC JOINTS

ABSTRACT OF THE DISCLOSURE

- 5 The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of:
- i) an inhibitor of a pro-inflammatory interleukin;
 - ii) an inhibitor of TNF- α synthesis;
 - 10 iii) an inhibitor of membrane-bound TNF- α ;
 - iv) an inhibitor of a natural receptor of TNF- α ;
 - v) an inhibitor of NO synthase,
 - vi) an inhibitor of PLA₂ enzyme;
 - vii) an anti-proliferative agent;
 - 15 viii) an anti-oxidant;
 - ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-I, IGF-II, and caspase inhibitors, and
 - x) an inhibitor of MMPs; and
 - 20 xi) an inhibitor of p38 kinase.